Monopar Therapeutics

Monopar Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. engages in building a drug development pipeline through the licensing and acquisition of oncology therapeutics in late preclinical and clinical development stages. Its product pipeline includes Validive, Camsirubicin and MNPR-101. The company was founded by Chandler D. Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing proprietary therapeutics for cancer patients. It also focuses on building a drug development pipeline through the licensing, and acquisition of therapeutics in late preclinical and clinical development stages. The company was founded by Chandler Drew Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.

Camsirubicin Phase 1b Clinical Trial Anticipated to Start in the U.S. in Q4 2021 Validive ® Phase 2b/3 VOICE Trial on Track for Reaching Interim Analysis in H1 2022

Monopar Therapeutics Reports Second Quarter 2021 Financial Results and Recent Business Updates

WILMETTE, Ill., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced it has successfully reached its target of 20 activated clinical trial sites in the Phase 2b portion of the VOICE trial.

Monopar Reaches Target Number of Clinical Sites in Phase 2b Portion of 2b/3 Validive® VOICE Trial

The FDA has signed off Monopar Therapeutics Inc's (NASDAQ: MNPR) IND to commence an open-label Phase 1b dose-escalation trial to evaluate camsirubicin plus pegfilgrastim in patients with advanced soft tissue sarcoma (ASTS). Enrollment will start in Q4 of 2021.

Monopar Stock Gains On Launch Of Early Stage Soft Tissue Cancer Trial With Camsirubicin

The stock price of Monopar Therapeutics Inc (NASDAQ: MNPR) increased by over 6% pre-market. This is why it happened.

MNPR Stock Price Increases Over 6% Pre-Market: Why It Happened

WILMETTE, Ill., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced clearance from the US Food and Drug Administration (FDA) to proceed under its IND with an open-label Phase 1b dose-escalation trial evaluating camsirubicin plus growth factor support (pegfilgrastim) in patients with advanced soft tissue sarcoma (ASTS). The Company anticipates dosing the first patient in the trial in the fourth quarter of this year.

Monopar Announces FDA Clearance to Proceed with Camsirubicin Clinical Trial Targeting Advanced Soft Tissue Sarcoma

WILMETTE, Ill., June 24, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that it will present its oropharyngeal cancer (OPC) patient population analysis of the Phase 2 Validive® (clonidine HCl MBT) trial for the prevention of chemoradiotherapy-induced severe oral mucositis in head and neck cancer at the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO) 2021 annual meeting. This analysis provided the rationale for the design of Monopar's Phase 2b/3 VOICE trial, which is open and accruing oropharyngeal cancer patients in the US.

Monopar to Present Results from Analysis of Oropharyngeal Cancer Patients in Completed Phase 2 Validive® Trial at MASCC/ISOO

Development of novel Camsirubicin analog expands Monopar's therapeutic pipeline Development of novel Camsirubicin analog expands Monopar's therapeutic pipeline

Monopar Announces New Drug Candidate, MNPR-202, and Enters into Collaboration Agreement with the National University of Singapore for Preclinical Evaluation in Cancer

The stock price of Monopar Therapeutics Inc (NASDAQ: MNPR) increased by over 3% pre-market. This is why it happened.

MNPR Stock Price: Over 3% Increase Pre-Market Explanation

First Patient Dosed in Validive ® Phase 2b/3 VOICE Clinical Trial Camsirubicin Run-in Clinical Trial Now Planned to Start in 2H 2021 Potential Utility Reported for MNPR-101 as Imaging Agent in Cancer Surgery

Monopar Therapeutics Reports First Quarter 2021 Financial Results and Recent Business Updates

BELOIT, Wis.--(BUSINESS WIRE)--NorthStar Medical Radioisotopes announced a corporate update describing progress in its key programs during the past year and upcoming milestones.

NorthStar Medical Radioisotopes Provides Updates on Corporate Progress and Upcoming Milestones

Monopar Therapeutics Inc (NASDAQ: MNPR) has announced the publication of a peer-reviewed study that demonstrated Monopar's Urokinase plasminogen activator (uPA) antibody fragment radiotracer could potentially identify breast cancers with uPA overexpression and monitor uPA activity during treatment using PET imaging. uPA is an established biomarker in current breast cancer clinical practice guidelines, and its presence is used to select appropriate drug treatment.

Monopar Therapeutics Is Trading Higher On Announcing Its uPA Radiotracer Along With Pet Imaging Can Detect Breast Cancer

The stock price of Monopar Therapeutics Inc. (Nasdaq: MNPR) has increased by over 15% pre-market. This is why it happened.

MNPR Stock Price Increased Over 15% Pre-Market: Why It Happened

WILMETTE, Ill., March 30, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced the publication of a peer-reviewed study titled “Engineered Antibody Fragment against the Urokinase Plasminogen Activator for Fast Delineation of Triple-Negative Breast Cancer by Positron Emission Tomography.” Urokinase plasminogen activator (uPA) is an established biomarker in current breast cancer clinical practice guidelines and its presence is used to select appropriate drug treatment. This study demonstrates the potential to identify breast cancers with uPA overexpression and monitor uPA activity during treatment using PET imaging and Monopar's uPA antibody fragment radiotracer. Monopar has a panel of proprietary antibodies and antibody fragments to uPA and its receptor uPAR (such as MNPR-101).

Monopar's uPA Antibody Fragment Radiotracer Shows Potential for PET Imaging of Breast Cancer in Preclinical Study

Validive ® Phase 2b/3 VOICE Clinical Trial Commenced Camsirubicin Phase 2 Clinical Trial Anticipated to Start in Q2 2021 MNPR-101-Conjugate Data Published in European Journal of Cancer

Monopar Therapeutics Reports Fourth Quarter and Full-Year 2020 Financial Results and Recent Business Updates

- Initial focus on use in bladder cancer surgery - Initial focus on use in bladder cancer surgery

Monopar Partners with Seasoned Medtech Executive to Explore the Potential of MNPR-101 as a uPAR Imaging Agent in Cancer Surgery

WILMETTE, Ill., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that Chandler D. Robinson, MD, Chief Executive Officer, is planning to present a Company overview at the following investor conferences in March:

Monopar Therapeutics to Present at Upcoming Investor Conferences

There are currently no FDA-approved drugs to prevent or treat chemoradiotherapy-induced SOM There are currently no FDA-approved drugs to prevent or treat chemoradiotherapy-induced SOM

Monopar Announces First Patient Dosed in its Phase 2b/3 VOICE Trial Evaluating Validive® for the Prevention of Chemoradiotherapy-Induced Severe Oral Mucositis (SOM) in Oropharyngeal Cancer (OPC)

The stock price of Monopar Therapeutics Inc (NASDAQ: MNPR) is trading at over 30% pre-market today. This is why it happened.

MNPR Stock Price Increases Over 30% Pre-Market: Why It Happened

WILMETTE, Ill., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced the publication of a peer-reviewed study in the European Journal of Cancer which shows the potential utility of MNPR-101 as a uPAR imaging agent to improve surgical outcomes in bladder cancer.

Monopar Announces Publication Demonstrating Potential Utility of MNPR-101 as an Imaging Agent to Improve Surgical Outcomes in Bladder Cancer

WILMETTE, Ill., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life and improve the quality of life for cancer patients, today announced the issuance of a patent covering composition of matter for MNPR-101 in Canada, adding to its existing protection in key markets around the world including the US, Europe and Japan.

Monopar Announces Issuance of Patent Covering Composition of Matter for MNPR-101 in Canada

Monopar Therapeutics (NASDAQ: MNPR) shares are trading higher Thursday after Roth Capital initiated coverage on the stock with a Buy rating and a price target of $49 per share. Monopar Therapeutics is a U.S. clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to improve clinical outcomes for cancer patients.

Why Monopar Therapeutics And EyePoint Pharma Are Trading Higher Today

The stock price of Monopar Therapeutics Inc (NASDAQ: MNPR) has increased over 100% pre-market today. This is why it happened.

MNPR Stock Price Increases Over 100% Pre-Market: Why It Happened

Monopar Therapeutics (MNPR) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Monopar Therapeutics (MNPR) Jumps: Stock Rises 7.4%

-Issued patent expands and strengthens Monopar's existing camsirubicin IP portfolio -Phase 2 initiation for camsirubicin in advanced soft tissue sarcoma remains on track for early 2021 

Monopar Announces Issuance of U.S. Patent Covering Compositions of Matter for a Novel Family of Camsirubicin Analogs

WILMETTE, Ill. and BELOIT, Wis., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) and NorthStar Medical Radioisotopes, LLC, which are jointly developing a urokinase plasminogen activator receptor targeted radio-immuno-therapeutic (uPRIT) for the potential treatment of severe COVID-19, today announced the selection of a uPRIT clinical candidate. Monopar and NorthStar partnered with IsoTherapeutics Group LLC to generate a panel of uPRIT leads, which were then screened by Aragen Bioscience Inc., resulting in the identification of a uPRIT clinical candidate plus several backup candidates.

News for Monopar Therapeutics Stock (MNPR)